Gemcitabine News and Research

RSS
Gemcitabine is the active ingredient in a drug that is used to treat pancreatic cancer that is advanced or has spread. It is also used together with other drugs to treat breast cancer that has spread, advanced ovarian cancer, and non-small cell lung cancer that is advanced or has spread. It is also being studied in the treatment of other types of cancer. Gemcitabine blocks the cell from making DNA and may kill cancer cells. It is a type of antimetabolite
Trial of new therapy for pancreatic cancer

Trial of new therapy for pancreatic cancer

Squalenoyl nanomedicines as potential therapeutics

Squalenoyl nanomedicines as potential therapeutics

Study: Collecting duct carcinoma

Study: Collecting duct carcinoma

Combining chemotherapy with radiation therapy after the surgical removal of cancer in the pancreas improves survival

Combining chemotherapy with radiation therapy after the surgical removal of cancer in the pancreas improves survival

FDA approval for Gemzar for ovarian cancer

FDA approval for Gemzar for ovarian cancer

Bortezomib extends lung cancer survival

Bortezomib extends lung cancer survival

Addition of gemcitabine to standard postoperative treatment increased pancreatic cancer patients' survival by 50 percent

Addition of gemcitabine to standard postoperative treatment increased pancreatic cancer patients' survival by 50 percent

New data show Enzastaurin's activity across multiple cancer cell lines

New data show Enzastaurin's activity across multiple cancer cell lines

Nicotine and chemotherapy not a good mix

Nicotine and chemotherapy not a good mix

Capecitabine and Gemcitabine help battle pancreatic cancer

Capecitabine and Gemcitabine help battle pancreatic cancer

Lung cancer drug approved for treating pancreatic cancer

Lung cancer drug approved for treating pancreatic cancer

New chemo combo means longer life for pancreatic cancer patients

New chemo combo means longer life for pancreatic cancer patients

First advance in pancreatic cancer treatment in a decade offers new hope

First advance in pancreatic cancer treatment in a decade offers new hope

A combination of chemotherapy drugs could double survival rates for pancreatic cancer

A combination of chemotherapy drugs could double survival rates for pancreatic cancer

Discovery of key molecule that controls the growth, spread and survival of pancreatic cancer cells

Discovery of key molecule that controls the growth, spread and survival of pancreatic cancer cells

Evaluation of BAY 43-9006 (Sorafenib) for pancreatic cancer

Evaluation of BAY 43-9006 (Sorafenib) for pancreatic cancer

FDA approves Tarceva (erlotinib)

FDA approves Tarceva (erlotinib)

Tarceva plus Gemcitabine improves survival compared to Gemcitabine alone

Tarceva plus Gemcitabine improves survival compared to Gemcitabine alone

Bladder-sparing treatment shows promise against cancer

Bladder-sparing treatment shows promise against cancer

Benefits of current therapeutic options for pancreatic cancer are eclipsed by their toxicity and inconvenience

Benefits of current therapeutic options for pancreatic cancer are eclipsed by their toxicity and inconvenience